Previous Article | Next Article 
Antimicrobial Agents and Chemotherapy, December 2001, p. 3341-3346, Vol. 45, No. 12
Department of Molecular and Cell Biology,
University of California, Berkeley,
California,1 and Department of
Microbiology2 and the First Department
of Prosthodontics,3 School of Dentistry,
Aichi-Gakuin University, Nagoya, Japan
Received 10 May 2001/Returned for modification 9 June 2001/Accepted 31 July 2001
We cloned a gene, bexA, that codes for a multidrug
efflux transporter from the chromosomal DNA of Bacteroides
thetaiotaomicron ATCC 29741 by using an Escherichia
coli Members of the Bacteroides
fragilis group are anaerobic bacteria of the highest clinical
relevance, and B. fragilis and Bacteroides thetaiotaomicron are often isolated from patients with suppurative anaerobic infections. They are gram-negative, obligately anaerobic organisms with a broad spectrum of recognized resistance to
antimicrobial agents (23), including aminoglycosides, most
of the penicillins and cephalosporins, and fluoroquinolones (except for
a few recently developed compounds such as trovafloxacin and
clinafloxacin) (2, 3).
Active multidrug efflux processes, usually involving secondary
transporters belonging to the major facilitator superfamily, small
multidrug resistance family, and resistance-nodulation-division (RND)
superfamily, are now known to be important, especially in the baseline
or intrinsic resistance of many bacteria to antimicrobial agents
(16, 21). More recently, a new family, the multidrug and
toxic compound extrusion (MATE) family, has been discovered (4), but its contribution to drug resistance has been
known only for a few isolated cases (12, 13).
We found previously that at least a portion of the remarkable
norfloxacin resistance (MICs, 16 to 32 µg/ml) of B. fragilis was attributed to active efflux of this agent
(12). To elucidate the efflux mechanism, we attempted to
clone the genes responsible for norfloxacin efflux from the chromosomal
DNAs of B. fragilis and B. thetaiotaomicron using
as the host an Escherichia coli mutant strain with defects
in multidrug efflux pumps. Here we report on the cloning and sequencing
of a gene, bexA, that is involved in the efflux of
norfloxacin, ciprofloxacin, and ethidium bromide from B. thetaiotaomicron. Interestingly, the BexA transporter is a member
of the MATE family.
Bacterial strains and growth conditions.
B.
fragilis ATCC 25285 and B. thetaiotaomicron ATCC 29741 5482 and were grown in general anaerobic GAM broth
(Nissui, Tokyo, Japan) and supplemented Trypticase soy broth (sTSB)
(12) in an anaerobic chamber.
0066-4804/01/$04.00+0 DOI: 10.1128/AAC.45.12.3341-3346.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
A MATE Family Multidrug Efflux Transporter Pumps
out Fluoroquinolones in Bacteroides
thetaiotaomicron
ABSTRACT
Top
Abstract
Introduction
Materials and Methods
Results and Discussion
References
acrAB acrEF mutant as a host. Although the initial recombinant construct contained other open
reading frames, the presence of bexA alone was
sufficient to confer to the E. coli host elevated levels
of resistance to norfloxacin, ciprofloxacin, and ethidium bromide.
Disruption of bexA in B. thetaiotaomicron
made the strain more susceptible to norfloxacin, ciprofloxacin, and
ethidium bromide, showing that this gene is expressed in this organism
and functions as a multidrug efflux pump. The deduced BexA protein
sequence was homologous to the protein sequence of Vibrio
parahaemolyticus NorM, a multidrug efflux transporter, and
thus, BexA belongs to the multidrug and toxic compound extrusion (MATE) family.
INTRODUCTION
Top
Abstract
Introduction
Materials and Methods
Results and Discussion
References
MATERIALS AND METHODS
Top
Abstract
Introduction
Materials and Methods
Results and Discussion
References
[K-12 supE44 lacU169 (
80
lacZM15) hsdR17 recA1 endA1 gyrA96 thi-1
relA1] (26) and AG102AX [K-12 argE3
thi-1 rpsL xyl mtl (gal-uvrB) marR1
acrAB::kan
acrEF::spc]. The latter strain was
constructed by transducing into AG102A (18) an
acrEF::spc allele (made in strain
JC7623 [9]) by deleting a 1,133-bp fragment between the
Eco47III site about 43% of the way into acrE
gene and the EcoRV site about 15% of the way into the
acrF gene and by introducing the 
interposon containing
the spectinomycin and streptomycin resistance marker
(22) in its place. E. coli strains were grown
at 37°C in Luria-Bertani (LB) broth or LB agar supplemented with ampicillin (20 µg/ml) or norfloxacin (50 ng/ml) when necessary.
Susceptibility testing. The MICs of drugs for E. coli and Bacteroides strains were determined by a broth microdilution assay in LB broth and sTSB, respectively, as described previously (12). For Bacteroides strains, gradient plate assays for MICs were also used when necessary (6). Cultures were incubated at 37°C overnight or for 2 days before the growth was assessed.
Gene cloning and sequencing. Chromosomal DNAs were prepared from cells of B. fragilis, B. thetaiotaomicron, and their mutants by the method of Smith et al. (30) and later with a MasterPure Genomic DNA purification kit (Epicentre Technologies, Madison, Wis.). The DNA was partially digested with Sau3AI, and digested fragments with sizes of 2 to 10 kb were separated by agarose gel electrophoresis. The DNA fragments extracted from the gels were ligated into vector pBR322 that was cut with BamHI and were then dephosphorylated with calf alkaline phosphatase. Cells of E. coli AG102AX were transformed with the ligated recombinant plasmids by electroporation and were spread on LB agar plates containing 50 ng of norfloxacin and 20 µg of ampicillin per ml. This led to the isolation of pBRBT20 containing 5.3 kb of B. thetaiotaomicron DNA. Other DNA manipulations were carried out by standard procedures as described elsewhere (26).
Subcloning of the insert in pBRBT20 were first performed by removing the 5' end of the insert by double digestion with EcoRV and BamHI and then inserting the shortened fragments into pBR322 digested with both EcoRV and BamHI, generating pBRBT201 (Fig. 1). The same fragment was also inserted into the multiple cloning site of pUC18, generating pUC18BT201. Digestion of pBRBT201 with MluI and EcoRV, followed by conversion of the MluI-digested terminus into a blunt end by filling in with T4 DNA polymerase (Takara DNA Blunting kit; Takara Biotechnology, Kyoto, Japan) and finally religation, generated pBRBT201ME (Fig. 1). Similarly, digestion of pBRBT201 with KpnI and BamHI, followed by conversion of the ends into blunt ends by digestion with mung bean nuclease and religation, gave pBR2012 (Fig. 1). In addition, subcloning of orf1 and bexA (Fig. 1) was performed by PCR amplification of these genes. Primers contained 5' extensions corresponding to EcoRV and BamHI target sequences for directed insertion into the pBR322 vector. The forward primers for orf1 and bexA started at residues 1,536 and 3,417 of the insert sequence in pBRBT20, respectively (or 85 and 147 bp upstream from the putative translation initiation codons of orf1 and bexA, respectively). The backward primers started at nucleotides 3,511 and 4,998, respectively, in the insert DNA of pBRBT20. The amplified fragments were inserted into pBR322 digested with EcoRV and BamHI, to yield plasmids pYEB (containing orf1) and pNEB (containing bexA); in these plasmids the cloned genes are inserted in the orientation in which the tet promoter of the vector could initiate their transcription.
|
Preparation of a gene disruption mutant in B. thetaiotaomicron. pGERM, a suicide vector for Bacteroides spp. (24), was used for preparation of a gene disruption mutant in B. thetaiotaomicron. This vector contains markers selectable in E. coli (bla) as well as in Bacteroides (ermG), replicates in E. coli, and can be mobilized for transfer into other bacteria because of the presence of a transfer origin (oriT) from plasmid RK2. It also carries the multiple cloning sites from pUC19. An approximately 1-kb internal fragment of bexA was cut out from pBRBT201 by digestion with PvuII and KpnI (Fig. 1) and was inserted into pGERM cut with SmaI and KpnI. E. coli S17-1 was transformed by this recombinant construct of pGERM containing an internal fragment of bexA, and a transformant was used as the donor in a mating with B. thetaiotaomicron ATCC 29741. In Bacteroides, pGERM derivatives cannot replicate, so a single homologous recombination with the chromosome within bexA, resulting in the insertion of pGERM sequence into this gene, is the most likely way to make the recipient cell erythromycin resistant (25, 29). Several erythromycin-resistant colonies recovered on plates with erythromycin (10 µg/ml) and gentamicin (200 µg/ml) (added in order to counterselect the donor strain, as Bacteroides spp. are intrinsically resistant to aminoglycosides [23]) were picked up for further analysis. These possible disruption mutants were tested for drug susceptibility and were then tested by genomic Southern analysis to confirm the occurrence of a disruption within bexA. A disruption mutant of bexA in B. thetaiotaomicron, OUT4, was isolated in this manner.
Genomic Southern blot analysis. Whole-plasmid DNAs of pBRBT20 (carrying the full insert DNA) and of pGERM recombinants pFY13A (containing the 0.65-kbp PstI-NsiI fragment, corresponding to an internal fragment of orf1) and pFY28 (containing the 1-kb KpnI-PvuII fragment, corresponding to an internal fragment of bexA) were biotinylated by nick translation with the BioNick Labeling System (Life Technologies, Frederick, Md.) and were then used as probes. Chromosomal DNAs were extracted as described above, digested with various restriction enzymes, and separated by gel electrophoresis. The Southern hybridization was detected by using the PhotoGene nucleic acid detection system (version 2.0; Life Technologies) according to the manufacturer's instructions.
Norfloxacin efflux assay. Norfloxacin accumulation in the cells was assayed by filtration of cells incubated with [14C]norfloxacin (12). Energy-dependent efflux was assessed by measurement of an increase in the level of accumulation upon the addition of a proton conductor, carbonyl cyanide m-chlorophenylhydrazone (CCCP), at 100 µM.
Nucleotide sequence accession number. The nucleotide sequence data have been deposited in the DDBJ database under accession no. AB067769.
| |
RESULTS AND DISCUSSION |
|---|
|
Top
Abstract
Introduction
Materials and Methods
Results and Discussion
References
|
|---|
Cloning of norfloxacin resistance gene from B.
thetaiotaomicron.
Since norfloxacin is actively pumped out
from B. fragilis (12) and B. thetaiotaomicron (unpublished data) and since the efflux is
catalyzed by a multidrug efflux pump (12), we tried to clone a gene(s) responsible for the efflux activity from these two
species. We successfully obtained from B. thetaiotaomicron but not from B. fragilis several recombinant plasmids that
decreased the norfloxacin susceptibility of the hypersusceptible
E. coli host strain lacking major multidrug efflux pumps
(strain AG102AX). One of the recombinants carrying a 5.3-kb insert,
pBRBT20, was used for further experiments (Fig. 1). As shown in Table
1, the norfloxacin and ethidium bromide
MICs were eight times higher and the ciprofloxacin MIC was four times
higher for AG102AX carrying pBRBT20 in comparison with the MICs
for the host strain or the strain containing the vector (pBR322) alone.
pBRBT20 did not increase the MIC of sparfloxacin, a lipophilic
fluoroquinolone, or the MICs of chlorampenicol and puromycin
(Table 1).
|
Sequence and characteristics of the putative gene products. Sequencing of the whole insert of pBRBT20 revealed three open reading frames shown as orfX, orf1, and orf2 (bexA) in Fig. 1. The orf2 product is predicted to contain 443 amino acids. BLASTP analysis of the sequence showed that it had strong similarity to the Vibrio parahaemolyticus NorM sequence (13) and that of its E. coli homolog, VdhE (14), as well as to those of many other proteins discussed below (see "Homology among members of the MATE family" below). Because of its homology with NorM, a known multidrug efflux transporter (13, 14), we propose that orf2 be named bexA (bacteroides exporter A). The family containing NorM was earlier defined as the MATE family (5).
The orf1 sequence is predicted to code for a protein of 618 amino acid residues. The BLASTP program suggested that this protein was a homolog of YidC, the E. coli protein recently shown to be involved in the insertion of membrane proteins (27, 28). Although the similarity was 39%, this involved the creation of many gaps corresponding to 19% of the aligned sequence, and it is not clear if this protein performs a similar function in Bacteroides. In any case, partial deletion of the insert sequence (see below) showed that this gene was unlikely to be involved in drug efflux. The orfX sequence, transcribed in the opposite direction, was predicted to code for a 403-residue protein, although its C terminus appears to be truncated in pBRBT20. This polypeptide showed strong similarity to the C-terminal halves of dozens of bacterial helicases, with the strongest similarity to those of Staphylococcus aureus (M63176_2) and Neisseria meningitidis (AJ391262-1). The function of this open reading frame is not clear, and its deletion did not affect the drug efflux phenotype, as described below.Subcloning of insert sequence. Several subclones were made from pBRRT20 in order to identify the gene essential for the norfloxacin resistance (Fig. 1). pBRBT201, in which an approximately 1.3-kb BamHI-EcoRV fragment (containing orfX) was deleted from the orfX-proximal end of the insert in pBRBT20, still exhibited the same level of resistance as the initial clone (Table 1). When the insert in pBRBT201 was further shortened on the 5' side by removing the EcoRV-MluI fragment that contains most of orf1, the resultant construct, pBRBT201ME, still maintained the high level of resistance (Table 1), showing that orf1 is not required for resistance. In contrast, pBRBT2012, with a deletion of the 0.6-kb KpnI-BamHI fragment at the bexA-proximal end of the insert, produced no increase in the level of resistance (Table 1), suggesting that the bexA-containing region is essential for resistance.
A promoter-like sequence (TATAAT and TGACAA) in front of orf1 shows strong similarity to the E. coli consensus
10 and 35 sequences, and no rho-independent terminator is
found downstream of orf1. Thus, in pBRBT201 and pBRBT2012,
which contain orf1 and its upstream sequence,
bexA could have been transcribed at least in part by
"readthrough" from orf1. The same explanation also applies to pBRBT20, in which the tetracycline promoter of the vector is
located at the 3' end (the right end in Fig. 1) of the insert. In
pBRBT201ME, which lacks this putative orf1 promoter, however, the tetracycline promoter of the vector pBR322, located on the
5' side of the insert (the left side in Fig. 1), was likely to have
been responsible for transcription of bexA in E. coli, as the sequence between orf1 and bexA
does not seem to contain a promoter sequence typical for E. coli. This hypothesis was supported by the observation that the
level of norfloxacin resistance was drastically reduced when the
tetracycline promoter was removed by cutting pBRBT201 with
AatII and EcoRV and then the upstream region and
the 5'-terminal portion of orf1 were removed by exonuclease III digestion (data not shown).
In order to confirm the conclusion that only bexA is needed
for antibiotic resistance, we amplified the orf1 and
bexA genes (with their upstream sequences) separately
through PCR and inserted these genes into pBR322 digested with
EcoRV and BamHI so that the tetracycline promoter
was located upstream from these genes. The results with these
constructs, pYEB and pNEB (Table 1), showed clearly that only
bexA is necessary for resistance. However, when the
bexA gene was inserted in the reverse orientation in plasmid pNBE, there was no increase in the level of resistance, suggesting that
the immediate upstream sequence of bexA indeed did not
function as an efficient promoter, at least in E. coli, and
that the successful expression of bexA in pNEB was due to
the presence of the tetracycline promoter of the vector.
The insert sequence in pBRBT201 was recloned in expression vector pUC18
in a direction that allowed the Plac promoter of the vector
to drive the transcription of both orf1 and bexA.
The resultant plasmid, pUC18BT201 increased the norfloxacin MIC for
strain DH5, in which the lacU169 deletion covers
lacI and allows the constitutive expression of the
Plac promoter (Table 1). Since, in contrast to strain
AG100AX, DH5 has no known defects in its multidrug efflux systems
and its OmpF porin level is not reduced by the marR mutation
(15), these features of AG100AX are not needed to see the
effect of the BexA pump in the increased level of resistance. Since NorM also pumps out aminoglycosides (14), we
tested the MICs of kanamycin and streptomycin using DH5/pUC18BT201.
No detectable increase in the MICs of these compounds for
DH5/pUC18BT201 in comparison with those for the parent
strain, DH5, was found (data not shown).
Homology among members of MATE family.
The MATE family was
reported to contain three branches: the NorM branch, a branch
containing several plant proteins (such as T51035 of Arabidopsis
thaliana; see below), and a branch containing E. coli
DinF (5). Among these three clusters, BexA had a high
degree of similarity to members of the NorM branch. Thus, the Expect
(E) value in BLASTP was 9 × 10
17 with V. parahaemolyticus NorM and 4 × 1020
with the Haemophilus influenzae homolog of NorM (HI1612).
The closest homologs of BexA in terms of E values, however,
were MATE family members that have not been tested for their efflux
functions and that have often been described as DinF homologs in
databases, such as Thermotoga maritima T0815 (AAD35897.1)
and Pyrococcus abysii PAB0243 (CAB49288.1), with
E values of 4 × 1030 and
2 × 1029, respectively. Nevertheless,
BexA does not appear to belong to the DinF branch or the plant protein
branch, because a two-sequence BLAST search between BexA and
representatives of these clusters (DinF of E. coli and
T05135 of A. thaliana [F7H19.220, listed as H19.22 in Fig.
3 of reference 5]) produced rather high E values (4 × 104 and 0.047, respectively).
|
Norfloxacin efflux activity.
As shown in Fig.
3, the addition of CCCP to E. coli AG102AX carrying pBRBT201 produced a large increase in the
level of norfloxacin accumulation. In addition, in the absence of CCCP
the steady-state level of norfloxacin accumulation in AG102AX/pBRBT201
was lower than that in the same host carrying the pBR322 vector alone.
AG102AX with no plasmid showed a similar, higher level of accumulation of norfoxacin (data not shown). These results suggest that this lower
steady-state level of accumulation in AG102AX/pBRBT201 was achieved by
an active efflux driven by the gene product expressed from the
recombinant plasmid in E. coli.
|
Effects of inhibitors.
We examined the effects of various
inhibitors of bacterial multidrug efflux pumps. As shown in Table
2, several compounds appeared to inhibit
the increase in the norfloxacin MIC, presumably by inhibiting drug
efflux. These compounds included reserpine and verapamil, both of which
are known to be inhibitors of major facilitator superfamily pumps
(1, 15), and MC-207,110, which is known to inhibit RND
pumps in Pseudomonas aeruginosa (10). We note
that reserpine and verapamil were earlier shown to decrease the
norfloxacin MICs for B. fragilis strains (12).
|
Disruption mutant of bexA. A disruption mutant of B. thetaiotaomicron bexA, OUT4, was isolated by using a suicide vector, pGERM (see Materials and Methods). Genomic Southern analysis confirmed that the bexA gene was interrupted in the mutant (data not shown). It was more susceptible than the parent strain, B. thetaiotaomicron ATCC 29741, to norfloxacin, ciprofloxacin, and ethidium bromide (Table 1), confirming that the gene is expressed in Bacteroides and contributes to its intrinsic resistance to fluoroquinolones.
Homologs in B. fragilis. Southern blot analysis with pGERM recombinants (pFY28) carrying an internal fragment of bexA as a probe did not reveal any homologous DNA fragments from B. fragilis ATCC 25285. Two clinical isolates of B. fragilis used previously (12) had no positive bands either, but B. thetaiotaomicron ATCC 29741 and 5482 contained similar positive bands carrying the genes (data not shown).
Since the genome sequencing of B. fragilis ATCC 25285 is in progress at the Sanger Centre and the raw sequences of the fragments are available at its website (www.sanger.ac.uk), we looked for homologs of the BexA protein by using the translated products of these sequences with the program TBLASTN. Indeed, the product of three sequences spliced together (Bf221 h02.q1c + Bf236a12 [reverse complement] + Bf142c11.qlc) had the strongest similarity (84% identity at the protein level), and at least three other sequences had strong similarity. However, this degree of similarity would not have been detected by Southern blotting under high-stringency conditions. We are trying to disrupt this and other homologs in B. fragilis in an attempt to evaluate their contribution to the drug resistance of this organism.Other possible mechanisms contributing to intrinsic fluoroquinolone resistance of Bacteroides. When we inactivated the bexA gene in B. thetaiotaomicron, the norfloxacin MIC decreased from 128 to 32 µg/ml (Table 1), yet the MIC for the mutant was still much higher than those for the wild-type strains of E. coli, for example. The presence of at least four homologs of bexA in B. fragilis suggests the possibility that there may also be other homologs of bexA in B. thetaiotaomicron which could contribute to the fluoroquinolone resistance. In addition, the target genes in various Bacteroides species might already contain "mutations" that make these targets resistant to fluoroquinolones, as has been demonstrated in several species of Mycobacterium (7). In fact, a partial sequence of B. thetaiotaomicron GyrA has recently been reported to contain an Asp86-to-Tyr change (17), corresponding to a frequent mutation (Asp87Tyr) found in fluoroquinolone-resistant mutants of E. coli (8, 32). The gyrA and gyrB genes of B. fragilis have been sequenced (19), and interestingly, Asp86 of the GyrA enzyme is again changed into phenylalanine. As the mutation of this residue to various neutral amino acids increases the level of fluoroquinolone resistance (8, 20, 32), this change may also make the target less susceptible in B. fragilis. Mutations of the target enzymes, however, usually produce only moderate levels of resistance, and the additional increase in efflux activity is needed for the production of very high levels of resistance, at least in E. coli (see reference 11 and references cited therein). These considerations suggest that active efflux plays a major role in the intrinsic fluoroquinolone resistance in Bacteroides. (However, in B. fragilis it has been reported that mutations in gyrA are usually introduced at later stages in the creation of strains with high levels of fluoroquinolone resistance [4].)
| |
ACKNOWLEDGMENTS |
|---|
This work was supported by a grant-in-aid for Science Promoted Research (grant 1006) from the Ministry of Education, Science, Sports and Culture of Japan (to F.Y.) and a grant from the U.S. Public Health Service (grant AI-09644) (to H.N.).
We thank N. Shoemaker for sending bacterial strains and plasmids for determination of the genetics of Bacteroides spp. and the Sanger Centre for making the B. fragilis genomic sequence freely available to the public.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Department of Molecular and Cell Biology, Room 229, Stanley Hall, University of California, Berkeley, CA 94720-3206. Phone: (510) 642-2027. Fax: (510) 643-9290. E-mail: nhiroshi{at}uclink4.berkeley.edu.
Present address: Department of Microbiology and Immunology,
Stanford University School of Medicine, Stanford, CA 94735.
| |
REFERENCES |
|---|
|
Top
Abstract
Introduction
Materials and Methods
Results and Discussion
References
|
|---|
| 1. |
Ahmed, M.,
C. M. Borsch,
A. A. Neyfakh, and S. Schuldiner.
1993.
Mutants of Bacillus subtilis multidrug transporter Mmr with altered sensitivity to the antihypertensive alkaloid reserpine.
J. Biol. Chem.
268:11086-11089 |
| 2. | Alekshun, M. N., and S. B. Levy. 2000. Bacterial drug response to survival threats, p. 323-366. In G. Storz, and R. Hengge-Aronis (ed.), Bacteria stress responses. ASM Press, Washington, D.C. |
| 3. | Appelbaum, P. A. 1999. Quinolone activity against anaerobes. Drugs 58:60-64. |
| 4. |
Bachoual, R.,
L. Dubreuil,
C.-J. Soussy, and J. Tankovic.
2000.
Roles of gyrA mutations in resistance of clinical isolates and in vitro mutants of Bacteroides fragilis to the new fluoroquinolone trovafloxacin.
Antimicrob. Agents Chemother.
44:1842-1845 |
| 5. | Brown, M. H., I. T. Paulsen, and R. A. Skurray. 1999. The multidrug efflux protein NorM is a prototype of a new family of transporters. Mol. Microbiol. 31:394-395[CrossRef][Medline]. |
| 6. |
Curiale, M. S., and S. B. Levy.
1982.
Two complementation groups mediate tetracycline resistance determined by Tn10.
J. Bacteriol.
151:209-215 |
| 7. | Guillemin, I., E. Cambau, and V. Jarlier. 1995. Sequences of conserved region in the A subunit of DNA gyrase from nine species of the genus Mycobacterium: phylogenetic analysis and implications for intrinsic susceptibility to quinolones. Antimicrob. Agents Chemother. 39:2145-2149[Abstract]. |
| 8. | Heisig, P. 1996. Genetic evidence for a role of parC mutations in development of high-level fluoroquinolone resistance in Escherichia coli. Antimicrob. Agents Chemother. 40:879-885[Abstract]. |
| 9. |
Kushner, S. R.,
A. Templin,
H. Nagaishi, and A. J. Clark.
1971.
Genetic recombination in Escherichia coli: the role of exonuclease I.
Proc. Natl. Acad. Sci. USA
68:824-827 |
| 10. |
Lomovskaya, O.,
M. S. Warren,
A. Lee,
J. Galazzo,
R. Fronko,
M. Lee,
J. Blais,
D. Cho,
S. Chamberland,
T. Renau,
R. Leger,
S. Hecker,
W. Watkins,
K. Hoshino,
H. Ishida, and V. J. Lee.
2001.
Identification and characterization of inhibitors of multidrug resistance efflux pumps in Pseudomonas aeruginosa: novel agents for combination therapy.
Antimicrob. Agents Chemother.
45:105-116 |
| 11. |
Mazzariol, A.,
Y. Tokue,
T. Kanegawa,
G. Cornaglia, and H. Nikaido.
2000.
High-level fluoroquinolone-resistant clinical isolates of Escherichia coli overproduce multidrug efflux protein AcrA.
Antimicrob. Agents Chemother.
44:3441-3443 |
| 12. |
Miyamae, S.,
H. Nikaido,
Y. Tanaka, and F. Yoshimura.
1998.
Active efflux of norfloxacin by Bacteroides fragilis.
Antimicrob. Agents Chemother.
42:2119-2121 |
| 13. |
Morita, Y.,
A. Kataoka,
S. Shiota,
T. Mizushima, and T. Tsuchiya.
2000.
NorM of Vibrio parahaemolyticus is an Na+-driven multidrug efflux pump.
J. Bacteriol.
182:6694-6697 |
| 14. |
Morita, Y.,
K. Kodama,
S. Shiota,
T. Mine,
A. Kataoka,
T. Mizushima, and T. Tsuchiya.
1998.
NorM, a putative multidrug efflux protein, of Vibrio parahaemolyticus and its homolog in Escherichia coli.
Antimicrob. Agents Chemother.
42:1778-1782 |
| 15. |
Neyfakh, A. A.
1992.
The multidrug efflux transporter of Bacillus subtilis is a structural and functional homolog of the Staphylococcus NorA protein.
Antimicrob. Agents Chemother.
36:484-485 |
| 16. | Nikaido, H. 1998. Antibiotic resistance caused by gram-negative multidrug efflux pumps. Clin. Infect. Dis. 27(Suppl. 1):S32-S41. |
| 17. |
Oh, H.,
N. El Amin,
T. Davies,
P. C. Appelbaum, and C. Edlund.
2001.
gyrA mutations associated with quinolone resistance in Bacteroides fragilis group strains.
Antimicrob. Agents Chemother.
45:1977-1981 |
| 18. |
Okusu, H.,
D. Ma, and H. Nikaido.
1996.
AcrAB efflux pump plays a major role in the antibiotic resistance phenotype of Escherichia coli multiple-antibiotic-resistance (Mar) mutants.
J. Bacteriol.
178:306-308 |
| 19. |
Onodera, Y., and K. Sato.
1999.
Molecular cloning of the gyrA and gyrB genes of Bacteroides fragilis encoding DNA gyrase.
Antimicrob. Agents Chemother.
43:2423-2429 |
| 20. |
Oram, M., and L. M. Fisher.
1991.
4-Quinolone resistance mutations in the DNA gyrase of Escherichia coli clinical isolates identified by using the polymerase chain reaction.
Antimicrob. Agents Chemother.
35:387-389 |
| 21. |
Paulsen, I. T.,
M. H. Brown, and R. A. Skurray.
1996.
Proton-dependent multidrug efflux systems.
Microbiol. Rev.
60:575-608 |
| 22. | Prentki, P., and H. M. Krisch. 1984. In vitro insertional mutagenesis with a selectable DNA fragment. Gene 29:303-313[CrossRef][Medline]. |
| 23. | Rasmussen, B. A., K. Bush, and F. P. Tally. 1997. Antimicrobial resistance in anaerobes. Clin. Infect. Dis. 24(Suppl. 1):S110-S120. |
| 24. | Salyers, A. A., G. Bonheyo, and N. B. Shoemaker. 2000. Starting a new genetic system: lessons from Bacteroides. Methods 20:35-46[CrossRef][Medline]. |
| 25. | Salyers, A. A., N. B. Shoemaker, A. Cooper, J. D'Elia, and J. A. Shipman. 1999. Genetic methods for Bacteroides species. Methods Microbiol. 29:229-276. |
| 26. | Sambrook, J., and D. W. Russell. 2001. Molecular cloning: a laboratory manual, 3rd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. |
| 27. | Samuelson, J. C., M. Minyong, F. Jiang, I. Moller, M. Wiedmann, A. Kuhn, G. J. Phillips, and R. E. Dalbey. 2000. YidC mediates membrane protein insertion in bacteria. Nature 406:637-641[CrossRef][Medline]. |
| 28. | Scotti, P. A., M. L. Urbanus, J. Brunner, J.-W. L. de Gier, G. von Heijne, C. van der Does, A. J. M. Driessen, B. Oudega, and J. Luirink. 2000. YidC, the Escherichia coli homologue of mitochondrial Oxa1p, is a component of the Sec translocase. EMBO J. 19:542-549[CrossRef][Medline]. |
| 29. |
Shoemaker, N. B.,
C. Getty,
P. E. Guthrie, and A. A. Salyers.
1986.
Two Bacteroides plasmids, pBFTM10 and pB8-51, contain transfer regions that are recognized by broad host range IncP plasmids and a conjugative Bacteroides tetracycline element.
J. Bacteriol.
166:959-965 |
| 30. | Smith, G. L. E., S. S. Socranski, and C. M. Smith. 1989. Rapid method for the purification of DNA from subgingival microorganisms. Oral Microbiol. Immunol. 4:47-51[Medline]. |
| 31. |
Thompson, J. D.,
D. G. Higgins, and T. J. Gibson.
1994.
CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice.
Nucleic Acids Res.
22:4673-4680 |
| 32. | Vila, J., J. Ruiz, P. Goni, and M. T. Jimenez de Anta. 1996. Detection of mutations in parC in quinolone-resistant clinical isolates of Escherichia coli. Antimicrob. Agents Chemother. 40:491-493[Abstract]. |
Antimicrobial Agents and Chemotherapy, December 2001, p. 3341-3346, Vol. 45, No. 12
0066-4804/01/$04.00+0 DOI: 10.1128/AAC.45.12.3341-3346.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Rosner, J. L., Martin, R. G.
(2009). An Excretory Function for the Escherichia coli Outer Membrane Pore TolC: Upregulation of marA and soxS Transcription and Rob Activity Due to Metabolites Accumulated in tolC Mutants. J. Bacteriol.
191: 5283-5292
[Abstract] [Full Text] -
Ge, Q., Yamada, Y., Zgurskaya, H.
(2009). The C-Terminal Domain of AcrA Is Essential for the Assembly and Function of the Multidrug Efflux Pump AcrAB-TolC. J. Bacteriol.
191: 4365-4371
[Abstract] [Full Text] -
Ohta, K.-y., Imamura, Y., Okudaira, N., Atsumi, R., Inoue, K., Yuasa, H.
(2009). Functional Characterization of Multidrug and Toxin Extrusion Protein 1 as a Facilitative Transporter for Fluoroquinolones. J. Pharmacol. Exp. Ther.
328: 628-634
[Abstract] [Full Text] -
Long, F., Rouquette-Loughlin, C., Shafer, W. M., Yu, E. W.
(2008). Functional Cloning and Characterization of the Multidrug Efflux Pumps NorM from Neisseria gonorrhoeae and YdhE from Escherichia coli. Antimicrob. Agents Chemother.
52: 3052-3060
[Abstract] [Full Text] -
Papaparaskevas, J., Pantazatou, A., Katsandri, A., Houhoula, D. P., Legakis, N. J., Tsakris, A., Avlamis, A.
(2008). Moxifloxacin resistance is prevalent among Bacteroides and Prevotella species in Greece. J Antimicrob Chemother
62: 137-141
[Abstract] [Full Text] -
Wexler, H. M.
(2007). Bacteroides: the Good, the Bad, and the Nitty-Gritty. Clin. Microbiol. Rev.
20: 593-621
[Abstract] [Full Text] -
Dastidar, V., Mao, W., Lomovskaya, O., Zgurskaya, H. I.
(2007). Drug-Induced Conformational Changes in Multidrug Efflux Transporter AcrB from Haemophilus influenzae. J. Bacteriol.
189: 5550-5558
[Abstract] [Full Text] -
Singh, A. K., Haldar, R., Mandal, D., Kundu, M.
(2006). Analysis of the Topology of Vibrio cholerae NorM and Identification of Amino Acid Residues Involved in Norfloxacin Resistance. Antimicrob. Agents Chemother.
50: 3717-3723
[Abstract] [Full Text] -
Pumbwe, L., Chang, A., Smith, R. L., Wexler, H. M.
(2006). Clinical significance of overexpression of multiple RND-family efflux pumps in Bacteroides fragilis isolates. J Antimicrob Chemother
58: 543-548
[Abstract] [Full Text] -
Pumbwe, L., Ueda, O., Yoshimura, F., Chang, A., Smith, R. L., Wexler, H. M.
(2006). Bacteroides fragilis BmeABC efflux systems additively confer intrinsic antimicrobial resistance. J Antimicrob Chemother
58: 37-46
[Abstract] [Full Text] -
Piddock, L. J. V.
(2006). Clinically Relevant Chromosomally Encoded Multidrug Resistance Efflux Pumps in Bacteria. Clin. Microbiol. Rev.
19: 382-402
[Abstract] [Full Text] -
Lau, S. Y., Zgurskaya, H. I.
(2005). Cell Division Defects in Escherichia coli Deficient in the Multidrug Efflux Transporter AcrEF-TolC. J. Bacteriol.
187: 7815-7825
[Abstract] [Full Text] -
Ueda, O., Wexler, H. M., Hirai, K., Shibata, Y., Yoshimura, F., Fujimura, S.
(2005). Sixteen Homologs of the Mex-Type Multidrug Resistance Efflux Pump in Bacteroides fragilis. Antimicrob. Agents Chemother.
49: 2807-2815
[Abstract] [Full Text] -
Poole, K.
(2005). Efflux-mediated antimicrobial resistance. J Antimicrob Chemother
56: 20-51
[Abstract] [Full Text] -
Kaatz, G. W., McAleese, F., Seo, S. M.
(2005). Multidrug Resistance in Staphylococcus aureus Due to Overexpression of a Novel Multidrug and Toxin Extrusion (MATE) Transport Protein. Antimicrob. Agents Chemother.
49: 1857-1864
[Abstract] [Full Text] -
Otsuka, M., Yasuda, M., Morita, Y., Otsuka, C., Tsuchiya, T., Omote, H., Moriyama, Y.
(2005). Identification of Essential Amino Acid Residues of the NorM Na+/Multidrug Antiporter in Vibrio parahaemolyticus. J. Bacteriol.
187: 1552-1558
[Abstract] [Full Text] -
Rafii, F., Park, M., Novak, J. S.
(2005). Alterations in DNA Gyrase and Topoisomerase IV in Resistant Mutants of Clostridium perfringens Found after In Vitro Treatment with Fluoroquinolones. Antimicrob. Agents Chemother.
49: 488-492
[Abstract] [Full Text] -
Franco, A. A.
(2004). The Bacteroides fragilis Pathogenicity Island Is Contained in a Putative Novel Conjugative Transposon. J. Bacteriol.
186: 6077-6092
[Abstract] [Full Text] -
Tikhonova, E. B., Zgurskaya, H. I.
(2004). AcrA, AcrB, and TolC of Escherichia coli Form a Stable Intermembrane Multidrug Efflux Complex. J. Biol. Chem.
279: 32116-32124
[Abstract] [Full Text] -
Ricci, V., Peterson, M. L., Rotschafer, J. C., Wexler, H., Piddock, L. J. V.
(2004). Role of Topoisomerase Mutations and Efflux in Fluoroquinolone Resistance of Bacteroides fragilis Clinical Isolates and Laboratory Mutants. Antimicrob. Agents Chemother.
48: 1344-1346
[Abstract] [Full Text] -
Ricci, V., Piddock, L.
(2003). Accumulation of garenoxacin by Bacteroides fragilis compared with that of five fluoroquinolones. J Antimicrob Chemother
52: 605-609
[Abstract] [Full Text] -
Golan, Y., McDermott, L. A., Jacobus, N. V., Goldstein, E. J. C., Finegold, S., Harrell, L. J., Hecht, D. W., Jenkins, S. G., Pierson, C., Venezia, R., Rihs, J., Iannini, P., Gorbach, S. L., Snydman, D. R.
(2003). Emergence of fluoroquinolone resistance among Bacteroides species. J Antimicrob Chemother
52: 208-213
[Abstract] [Full Text] -
Rouquette-Loughlin, C., Dunham, S. A., Kuhn, M., Balthazar, J. T., Shafer, W. M.
(2003). The NorM Efflux Pump of Neisseria gonorrhoeae and Neisseria meningitidis Recognizes Antimicrobial Cationic Compounds. J. Bacteriol.
185: 1101-1106
[Abstract] [Full Text] -
Li, X.-Z., Poole, K., Nikaido, H.
(2003). Contributions of MexAB-OprM and an EmrE Homolog to Intrinsic Resistance of Pseudomonas aeruginosa to Aminoglycosides and Dyes. Antimicrob. Agents Chemother.
47: 27-33
[Abstract] [Full Text] -
Tikhonova, E. B., Wang, Q., Zgurskaya, H. I.
(2002). Chimeric Analysis of the Multicomponent Multidrug Efflux Transporters from Gram-Negative Bacteria. J. Bacteriol.
184: 6499-6507
[Abstract] [Full Text] -
Braibant, M., Guilloteau, L., Zygmunt, M. S.
(2002). Functional Characterization of Brucella melitensis NorMI, an Efflux Pump Belonging to the Multidrug and Toxic Compound Extrusion Family. Antimicrob. Agents Chemother.
46: 3050-3053
[Abstract] [Full Text]
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»